By All Criteria That Matter To Me, Coloplast Is The Ideal Stock
- Coloplast is the only stock that passed the stock screening process for my "sustainable portfolio" with distinction.
- The company's focus on intimate healthcare provides a unique angle on healthcare as investment theme.
- A track record of 19 consecutive years of increased dividends would make it in the categories used by David Fish a Dividend Contender on a DKK-basis.
- Coloplast sports a strong balance sheet with no interest-bearing debt at all.
- The business has been growing revenues organically at a rate of 6 to 7% per annum in recent years and impresses by converting an increasing share of its revenues into cash.
There are no Transcripts on CLPBY.
We currently have no Breaking News on this stock.
CLPBY vs. ETF Alternatives
Other News & PR